Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
NCT ID: NCT01132053
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
126 participants
OBSERVATIONAL
2004-06-30
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
NCT01730131
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
NCT05982925
Inflammatory and Infectious Diseases of the Nervous System
NCT02435810
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
NCT04453917
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PML
These are subjects who have confirmed PML.
No interventions assigned to this group
Control
These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Presence of confounding neurological disorder such as brain neoplasm etc.
In addition patients with a contraindication to MRI examination will be excluded from study. Contraindications to the MRI examination include:
1. Medically unstable or hematological, renal, or hepatic dysfunction.
2. Cardiac pacemaker
3. Internal clips,
4. Metal implants, or external clips with 10 mm of the head.
5. Metal in the eyes.
6. Pregnant
7. Claustrophobia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Beth Israel Deaconess Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Sabrina Tan
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chen S Tan, MD
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Description of PML studies at BIDMC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NS 047029
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2004P000089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.